Case Report

Extramedullary Hematopoiesis in a Sentinel Lymph Node as an Early Sign of Chronic Myelomonocytic Leukemia

Joslin M. Bowen,1 Anamarija M. Perry,2 Erin Quist,3 and Mojtaba Akhtari4

1Physicians Laboratory, 4840 F Street, Omaha, NE 68117, USA
2Department of Pathology, University of Manitoba, MS559S Thorlakson Building, 820 Sherbrook Street, Winnipeg, MB, Canada R3A 1R9
3Department of Pathology and Microbiology, University of Nebraska Medical Center, 985900 Nebraska Medical Center, Omaha, NE 68198, USA
4Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, University of Southern California (USC) and Norris Cancer Center, USC University Hospital, 1441 Eastlake Avenue, Norris Topping Tower 3463, MC 9172, Los Angeles, CA 90033-9172, USA

Correspondence should be addressed to Anamarija M. Perry; anamarijamorovic@hotmail.com

Received 26 February 2015; Revised 27 March 2015; Accepted 3 April 2015

Academic Editor: Sami Shousha

Copyright © 2015 Joslin M. Bowen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic malignancy with features of both a myeloproliferative neoplasm and a myelodysplastic syndrome [1, 2]. The 2008 World Health Organization (WHO) classification defines CMML using the following criteria: (1) persistent monocytosis of \( > 1 \times 10^9 \) in the peripheral blood (PB), (2) absence of Philadelphia chromosome and BCR-ABL1 fusion gene, (3) no rearrangement of PDGFRα or PDGFRβ in the cases with eosinophilia, (4) fewer than 20% blasts and/or promonocytes in the PB and bone marrow (BM), and (5) dysplasia involving one or more myeloid lineages [1]. Clinically, PB and BM are always involved. Extramedullary leukemic infiltration can be seen in CMML, and it is most commonly encountered in spleen and liver [1, 3]. Disease less frequently involves other sites such as skin and genitourinary tract [4–6]. Lymph node enlargement in CMML has been reported in the older literature (i.e., before the advent of 2001 WHO classification [7]) in 14% to 30% of patients [3, 8]; however, there are very few reports in the literature that histologically describe involved lymph nodes [8–11].

Herein, we report an unusual case of a 72-year-old female who was found to have extramedullary hematopoiesis (EMH) in a sentinel lymph node that was excised during mastectomy for lobular breast carcinoma. One year later bone marrow biopsy was performed due to persistent anemia, thrombocytopenia, and monocytosis and the patient was diagnosed with CMML. Our case illustrates the importance of recognizing EMH in a lymph node during routine histological examination, especially in adults. Proliferation of bone marrow elements in a lymph node, in a patient with no known hematologic disorder, should trigger immediate bone marrow evaluation, as this could be the first clue in diagnosing underlying bone marrow disorder.

1. Introduction

Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic malignancy characterized by overlapping features of both a myeloproliferative neoplasm and a myelodysplastic syndrome [1, 2]. The 2008 World Health Organization (WHO) classification defines CMML using the following criteria: (1) persistent monocytosis of \( > 1 \times 10^9 \) in the peripheral blood (PB), (2) absence of Philadelphia chromosome and BCR-ABL1 fusion gene, (3) no rearrangement of PDGFRα or PDGFRβ in the cases with eosinophilia, (4) fewer than 20% blasts and/or promonocytes in the PB and bone marrow (BM), and (5) dysplasia involving one or more myeloid lineages [1]. Clinically, PB and BM are always involved. Extramedullary leukemic infiltration can be seen in CMML, and it is most commonly encountered in spleen and liver [1, 3]. Disease less frequently involves other sites such as skin and genitourinary tract [4–6]. Lymph node enlargement in CMML has been reported in the older literature (i.e., before the advent of 2001 WHO classification [7]) in 14% to 30% of patients [3, 8]; however, there are very few reports in the literature that histologically describe involved lymph nodes [8–11].

Herein, we report an unusual case of a 72-year-old female who was found to have extramedullary hematopoiesis in a sentinel lymph node, excised for lobular carcinoma of the breast, and was diagnosed with CMML one year later. Extramedullary hematopoiesis in a sentinel lymph node can be considered as an early sign of CMML.
2. Case Presentation

A 72-year-old lady was found to have a 1 cm spiculated lesion on screening mammography. She underwent mastectomy and sentinel lymph node excision for a biopsy proven lobular breast carcinoma. Sentinel lymph node showed overall preserved architecture with follicular and paracortical hyperplasia and dilated sinuses. In the paracortical area (Figure 1(a)) and the sinuses (Figure 1(b)) there were small clusters of immature erythroid cells, as well as scattered megakaryocytes, consistent with extramedullary hematopoiesis (EMH). Megakaryocytes showed dyspoietic changes including hyperlobation and hyperchromatic nuclei. There was no significant dyspoiesis in erythroid precursors. Myeloid precursors were not prominent component of the EMH. There was no morphological increase in blasts or promonocytes. Immunohistochemical stain for Factor VIII further highlighted the megakaryocytes (Figure 2). One year later, the patient was referred to a hematologist for worsening anemia (hemoglobin 10.5 g/dL; normal range, 11.5–15.5 g/dL) and thrombocytopenia (platelets ranged from 89,000 to 124,000/μL; normal range, 150,000–400,000/μL), and persistent monocytosis (absolute monocyte count 1.2 × 10³/μL; normal range, 0.1–1.0 × 10³/μL). Of note, absolute monocyte count at the time of the sentinel lymph node biopsy one year prior was 1.5 × 10³/μL. The patient underwent a bone marrow biopsy which showed markedly hypercellular marrow for patient’s age (80% cellularity; Figure 3(a)). Dyspoiesis was present in all three hematopoietic lineages but most prominent in megakaryocytes that showed clustering with numerous small and hypolobated forms (Figure 3(b)). There was prominent monocytosis with 18% monocytes by differential count. Blasts (including promonocytes) were not significantly increased and by differential counts were <5% in the PB and <10% in the BM. There was moderate (grade 2/3) diffuse reticulin fibrosis. Conventional cytogenetic studies showed the following karyotype: 46,XX,del(20)(q11.2q13.3)[20]. Fluorescence in situ hybridization studies showed del20q12 and del20q13. Molecular studies were negative for JAK2 V617F mutation and for BCL-ABL1 fusion gene. The patient was diagnosed with CMML-1. She became symptomatic due to progressive anemia and was initially treated with 6 cycles of azacitidine, to which she responded; however, she lost her response after 8 cycles. Her regimen was then switched to decitabine, to which she had a fair response. Her general condition started deteriorating; she had prolonged neutropenia and passed away due to septic shock.

3. Discussion

Extramedullary hematopoiesis is a result of conditions that disrupt the bone marrow microenvironment, facilitating the
egression of precursor cell, with an increase in circulating mature and immature marrow elements. After birth, there is normally very little proliferation of hematopoietic elements outside the marrow. Extramedullary hematopoiesis occurs in a number of conditions, including benign hematologic disorders (e.g., thalassemia, hereditary spherocytosis, sickle cell anemia, and congenital dyserythroblastoid anemia), hematopoietic neoplasms, stromal disorders of the marrow (e.g., osteoporosis), nonhematopoietic tumors, infectious, and storage diseases, as well as disorders of the circulation [12, 13]. In a case of hematopoietic neoplasm that involves extramedullary site, better term to use is neoplastic myeloid proliferation (NMP), to differentiate it from EMH that occurs as a consequence of benign disorders. Neoplastic myeloid proliferation can be seen in association with myeloproliferative neoplasms, myelodysplastic syndromes, myelodysplastic/myeloproliferative neoplasms, and other myeloid derived malignancies [13]. Extramedullary hematopoiesis has been reported in almost all body sites, including lymph nodes [12–14].

In the case of our patient, EMH was an incidental finding in a sentinel lymph node that was excised due to lobular carcinoma of the breast. Proliferation of bone marrow elements in a lymph node is not considered normal in an adult and should prompt an immediate search for an underlying bone marrow disorder [13]. However, our patient was not evaluated for hematologic neoplasm until a year later when she was referred to a hematologist for worsening cytopenias and was diagnosed with CMML. Median survival of CMML patients is 20–40 months and multiple drugs are being used in treatment of this disease [1, 2]. Delay in diagnosis and treatment could potentially shorten patient’s survival. In children, the presence of EMH in lymph nodes could indicate undiagnosed benign hematologic disorder, and lymphadenopathy with EMH may be an initial manifestation [13]. Even though lymph node involvement, detected by imaging studies, is not uncommon in patients with myeloproliferative/myelodysplastic neoplasms, routine lymph node biopsies are not performed in these patients [3, 8, 14]. Sudden appearance of lymphadenopathy can also indicate transformation to acute myeloid leukemia/myeloid sarcoma [11].

Several authors have reported EMH in axillary lymph nodes following neoadjuvant therapy for breast cancer [15–17]. This finding is likely related to use of bone marrow suppressing chemotherapeutic agents along with granulocyte colony stimulating factors in these patients [16]. Extramedullary hematopoiesis in a lymph node is a potential diagnostic pitfall in these cases as it could be mistaken for metastatic carcinoma. Furthermore, presence of EMH can be especially problematic when evaluating lymph nodes during frozen section where morphology is frequently less than optimal [15, 16]. Our patient did not receive neoadjuvant chemotherapy prior to lymph node sampling, but it is important to keep this “phenomenon” in differential diagnosis in patients with a history of chemotherapy.

In conclusion, our case illustrates the importance of recognizing EMH in a lymph node during routine histological examination, especially in adults, since it can be an early sign of an underlying hematological malignancy. Proliferation of bone marrow elements in a lymph node, in a patient with no known hematologic disorder, should trigger immediate bone marrow evaluation, as this could be the first clue in diagnosing underlying bone marrow disorder.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

[1] A. Orazi, J. M. Bennett, U. Germing, R. D. Brunning, B. J. Bain, and J. Thiele, “Chronic myelomonocytic leukemia,” in WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, S. H. Swerdlow, E. Campo, N. L. Harris et al., Eds., pp. 76–79, IARC, Lyon, France, 2008.

[2] M. M. Patnaik, S. A. Parikh, C. A. Hanson, and A. Tefferi, “Chronic myelomonocytic leukemia: a concise clinical and pathophysiological review,” British Journal of Haematology, vol. 165, no. 3, pp. 273–286, 2014.

[3] Groupe Francais de Cytogenetique Hématologique, “Chronic myelomonocytic leukemia: single entity or heterogeneous disorder?: a prospective multicenter study of 100 patients,” Cancer Genetics and Cytogenetics, vol. 55, no. 1, pp. 57–65, 1991.

[4] N. M. Corcoran, A. Tsui, A. J. Costello, and D. Bouchier-Hayes, “Unilateral testicular mass in man with chronic myelomonocytic leukemia: unusual presentation of chronic myelomonocytic leukemia sequel,” Urology, vol. 65, no. 5, p. 1001, 2005.

[5] E. S. Hyams, R. Gupta, J. Melamed, S. S. Taneja, and O. Shah, “Renal involvement by chronic myelomonocytic leukemia requiring nephroureterectomy,” Reviews in Urology, vol. 11, no. 1, pp. 33–37, 2009.

[6] R. A. Mathew, J. M. Bennett, J. J. Liu et al., “Cutaneous manifestations in CMML: indication of disease acceleration or transformation to AML and review of the literature,” Leukemia Research, vol. 36, no. 1, pp. 72–80, 2012.

[7] E. S. Jaffe, N. L. Harris, H. Stein et al., Eds., World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon, France, 2001.

[8] A. E. Hunter, N. H. Russell, and I. Ellis, “Extramedullary haemopoiesis as a cause of mediastinal lymphadenopathy in chronic myelomonocytic leukaemia,” Clinical and Laboratory Haematology, vol. 12, no. 4, pp. 465–469, 1990.

[9] A. Manoharan, “Malignant pleural effusion in chronic myelomonocytic leukaemia,” Thorax, vol. 46, no. 6, pp. 461–462, 1991.

[10] X. Gong, X. Lu, Y. Fu et al., “Cytological features of chronic myelomonocytic leukaemia in pleural effusion and lymph node fine needle aspiration,” Cytopathology, vol. 21, no. 6, pp. 411–413, 2010.

[11] T. Derlin, T. S. Clauditz, and P. Bannas, “18F-FDG PET/CT for staging and detection of extramedullary organ involvement in chronic myelomonocytic leukemia,” Clinical Nuclear Medicine, vol. 39, no. 9, pp. 811–812, 2014.

[12] D. P. O’Malley, Y. S. Kim, S. L. Perkins, L. Baldridge, B. E. Juliar, and A. Orazi, “Morphologic and immunohistochemical evaluation of splenic hematopoietic proliferations in neoplastic...
and benign disorders,” *Modern Pathology*, vol. 18, no. 12, pp. 1550–1561, 2005.

[13] D. P. O’Malley, “Benign extramedullary myeloid proliferations,” *Modern Pathology*, vol. 20, no. 4, pp. 405–415, 2007.

[14] D. Sohawon, K. K. Lau, T. Lau, and D. K. Bowden, “Extra-
medullary haematopoiesis: a pictorial review of its typical and
atypical locations,” *Journal of Medical Imaging and Radiation
Oncology*, vol. 56, no. 5, pp. 538–544, 2012.

[15] E. K. A. Millar, S. Inder, and J. Lynch, “Extramedullary
haematopoiesis in axillary lymph nodes following neoadjuvant
chemotherapy for locally advanced breast cancer—a potential
diagnostic pitfall,” *Histopathology*, vol. 54, no. 5, pp. 622–623,
2009.

[16] C. Prieto-Granada, N. Setia, and C. N. Otis, “Lymph node
extramedullary hematopoiesis in breast cancer patients receiv-
ing neoadjuvant therapy: a potential diagnostic pitfall,” *Inter-
national Journal of Surgical Pathology*, vol. 21, no. 3, pp. 264–266,
2013.

[17] A. S. Takhar, A. Ney, M. Patel, and A. Sharma, “Extramedullary
haematopoiesis in axillary lymph nodes following neoadjuvant
chemotherapy for locally advanced breast cancer,” *BMJ Case
Reports*, 2013.